Skip to main content

Questcor Pharmaceuticals



) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 1.4%. By the end of trading, Questcor Pharmaceuticals fell $2.28 (-5.7%) to $37.73 on average volume. Throughout the day, 3.2 million shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 2.7 million shares. The stock ranged in price between $37.43-$40.18 after having opened the day at $39.90 as compared to the previous trading day's close of $40.01. Other company's within the Health Care sector that declined today were:

Graymark Healthcare



), down 17.5%,

Horizon Pharma



), down 17.4%,




), down 14.8%, and

Dehaier Medical Systems



), down 12.8%.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides prescription drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Questcor Pharmaceuticals has a market cap of $2.43 billion and is part of the


industry. The company has a P/E ratio of 18.7, below the average drugs industry P/E ratio of 23.8 and above the S&P 500 P/E ratio of 17.7. Shares are down 3.8% year to date as of the close of trading on Thursday. Currently there are nine analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and one rates it a hold.

TheStreet Ratings rates Questcor Pharmaceuticals as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value.

On the positive front,

ProPhase Labs



), up 19.1%,




), up 15.5%,




), up 13.4%, and




), up 13.1%, were all gainers within the health care sector with




) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR



) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care